Desmopressin increases IGF-binding protein-1 in humans.
BACKGROUND
IGF binding protein-1 (IGFBP-1) is essential for IGF-I bioavailability. High levels of IGFBP-1 are encountered in critically ill patients and are a good predictor marker in acute myocardial infarction. The mechanisms responsible for the elevated IGFBP-1 levels in these conditions are still unclear. Interestingly, high levels of vasopressin have been reported in the above-mentioned conditions.


OBJECTIVE
To study the effect of vasopressin on IGFBP-1 in humans.


METHODS
Placebo-controlled cross-over study in patients with central diabetes insipidus (CDI) in whom potential interference from endogenous vasopressin secretion is minimized. After a 3-day desmopressin washout period, each patient received i.v. saline on day 1 and desmopressin (3 mug) on day 2. Blood samples were taken after administration, every 2 h during the whole night, starting at 2000 h.


METHODS
Fourteen inpatients with CDI in an endocrinology department of a university hospital.


RESULTS
Serum IGFBP-1 increased within 4 h after 1-desamino-8-d-arginine vasopressin (DDAVP) by 375+/-73%, compared with a spontaneous fasting increase by 252+/-46% following placebo administration (P<0.05). No changes were registered in the levels of either classically regulators of IGFBP-1 (insulin, glucagon, and cortisol) or of IGF-I and glucose. The decrease in plasma osmolarity induced by DDAVP did not precede the increase in IGFBP-1.


CONCLUSIONS
DDAVP increases serum levels of IGFBP-1. Further investigation is essential to unravel the clinical potential of this interaction in conditions associated with high IGFBP-1 levels.
Catrina
S B
SB
Department of Molecular Medicine and Surgery, Karolinska Institute, L1:O1, Stockholm S-17176, Sweden. sergiu-bogdan.catrina@ki.se
Rotarus
R
R
Botusan
I R
IR
Coculescu
M
M
Brismar
K
K
D050034:Antidiuretic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018592:Cross-Over Studies; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology* / Q000627:therapeutic use*; D020790:Diabetes Insipidus, Neurogenic / Q000097:blood / Q000188:drug therapy*; D005934:Glucagon / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood* / Q000378:metabolism; D010919:Placebos
D050034:Antidiuretic Agents; C032231:IGFBP1 protein, human; D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D010919:Placebos; D005934:Glucagon; D003894:Deamino Arginine Vasopressin; D006854:Hydrocortisone